The clinical use of doxorubicin (DOX) is largely limited by its cardiotoxicity. Previous studies have shown that jaceosidin has many biological activities. However, little is known about whether jaceosidin can attenuate DOX‐related acute cardiotoxicity. Here, we investigated the therapeutic effects of jaceosidin on DOX‐induced acute cardiotoxicity. Mice were intraperitoneally injected with a single dose of DOX to establish an acute cardiac injury model. To explore the protective effects, mice were orally administered jaceosidin daily for 7 days, with dosing beginning 2 days before DOX injection. The results demonstrated that jaceosidin dose‐dependently reduced free radical generation, inflammation accumulation, and cell loss induced by DOX in cardiomyocytes. Further studies showed that jaceosidin treatment inhibited myocardial oxidative damage and the inflammatory response and attenuated myocardial apoptotic death, thus improving cardiac function in mice injected with DOX. The inhibitory effects of jaceosidin on DOX‐related acute cardiotoxicity were mediated by activation of the sirtuin1 (Sirt1) signaling pathway. Jaceosidin lost its protective effect against DOX‐related injury in Sirt1‐deficient cardiomyocytes and mice. In conclusion, jaceosidin has protective potential in treating DOX‐related cardiac injury through activation of the Sirt1 signaling pathway.
Pathological myocardial hypertrophy is regulated by multiple pathways. However, its underlying pathogenesis has not been fully explored. The goal of this work was to elucidate the function of polypeptide N-acetylgalactosaminyltransferase 4 (GALNT4) in myocardial hypertrophy and its underlying mechanism of action. We illustrated that GALNT4 was upregulated in the models of hypertrophy. Two cardiac hypertrophy models were established through partial transection of the aorta in GALNT4-knockout (GALNT4-KO) mice and adeno-associated virus 9-GALNT4 (AAV9-GALNT4) mice. The GALNT4-KO mice demonstrated accelerated cardiac hypertrophy, dysfunction, and fibrosis, whereas the opposite phenotype was observed in AAV9-GALNT4 mice. Similarly, GALNT4 overexpression mitigated the degree of phenylephrine-induced cardiomyocyte hypertrophy in vitro whereas GALNT4 knockdown aggravated the hypertrophy. In terms of mechanism, GALNT4 deficiency increased the phosphorylation and activation of ASK1 and its downstream targets (JNK and p38), whereas GALNT4 overexpression inhibited activation of the ASK1 pathway. Furthermore, we demonstrated that GALNT4 can directly bind to ASK1 inhibiting its N-terminally mediated dimerization and the subsequent phosphorylation of ASK1. Finally, an ASK1 inhibitor (iASK1) was able to reverse the effects of GALNT4 in vitro. In summary, GALNT4 may serve as a new regulatory factor and therapeutic target by blocking the activation of the ASK1 signaling cascade.
16 October 2023 in Free Radical Biology and Medicine
Salvia miltiorrhiza Bge. (S. miltiorrhiza) is an important herbal medicine, and the researches mainly focused on the roots of S. miltiorrhiza rather than the above-ground parts. Therefore, the detailed research on the above-ground parts of S. miltiorrhiza is still unclear. This study aimed to elucidate the constituents of the above-ground parts of S. miltiorrhiza extract (SME) and evaluate its effect on endothelial cell injury. For this purpose, the constituents of SME were identified by ultra performance liquid chromatography tandem mass spectrometry, and 41 compounds were determined, including terpenes, phenylpropanoids, flavonoids, sterols and phenolic acids. The effect of SME on endothelial cell was evaluated using isoproterenol (ISO)-treated C57BL/6 mice and hypoxia-treated HUVECs, and the results revealed that SME could improve endothelial cell injury in ISO-induced myocardial infarction model and hypoxia-induced HUVECs injury. In this process, SME could inhibit reactive oxygen species production, decrease the levels of malondialdehyde, lactic dehydrogenase, pyruvic acid, intracellular iron ions and sugar, and increase the levels of glutathione. Meanwhile, SME could improve the abnormal expressions of apoptosis-, glycolysis- and ferroptosis-related proteins. Taken together, our data demonstrated that SME treatment could alleviate endothelial cell injury by regulating HIF-1α mediated glycolysis and ferroptosis signals.